ArticleMolecular neurobiology2025
Orexin-A and Circadian Disruption in Alzheimer's Disease: Implications for Amyloid-Beta Pathology.
Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Alzheimer's disease (AD) is characterized by cognitive decline, circadian rhythm disruptions, and accumulation of Aβ plaques. Orexin-A, a neuropeptide involved in regulating sleep and circadian rhythms, has been implicated in these processes, although its specific role in modulating β-amyloid (Aβ) aggregation remains unclear. This study investigates how orexin-A influences Aβ aggregation and its impact on cognitive and circadian dysfunctions in AD mice subjected to acute sleep deprivation (ASD). Behavioural assessments showed significant cognitive deficits following ASD, including impaired recognition and spatial memory. Proteomic analysis revealed 1380 modulated proteins, including 105 associated with AD, 56 with cognitive functions, 11 with circadian rhythm, and six involved in Aβ clearance. Further analysis showed dysregulation of Clock and Bmal1 levels, along with reduced orexin-A expression after ASD. Since orexin-A regulates both sleep and circadian rhythm, investigating its role in modulating Aβ aggregation is essential for understanding the pathophysiology of AD. To explore this, we performed molecular dynamics (MD) simulations to gain insights into the molecular interactions between orexin-A and Aβ. Analysis revealed that orexin-A binds Aβ with high affinity and effectively inhibits its aggregation, suggesting a potential mechanism for reducing Aβ-induced neurotoxicity. These results suggest that orexin-A may play an important role in modulating Aβ aggregation and circadian dysfunction in AD, as supported by simulation results. Further studies manipulating orexin-A levels are needed to confirm its role in this context. Our findings highlight orexin-A as a potential therapeutic target for slowing cognitive decline and neurodegeneration in AD by restoring circadian and sleep-wake regulation.
Indexed as
Identifiers
41335394What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.